Stockscreener 앱 받기
1.925
0.77%
-0.015
전일 마감가:
$1.94
열려 있는:
$1.92
하루 거래량:
3.47M
Relative Volume:
1.76
시가총액:
$190.92M
수익:
$11.16M
순이익/손실:
$-148.13M
주가수익비율:
-1.2118
EPS:
-1.5885
순현금흐름:
$-112.35M
1주 성능:
+5.77%
1개월 성능:
+7.54%
6개월 성능:
+15.96%
1년 성능:
+10.63%
1일 변동 폭
$1.755
$1.93
1주일 범위
$1.75
$2.11
52주 변동 폭
$1.38
$3.535
Caribou Biosciences Inc Stock (CRBU) Company Profile
명칭
Caribou Biosciences Inc
전화
510-982-6030
주소
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
1.925 | 190.92M | 11.16M | -148.13M | -112.35M | -1.5885 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-11-08 | 개시 | Cantor Fitzgerald | Neutral |
| 2023-10-31 | 개시 | Evercore ISI | Outperform |
| 2023-07-11 | 개시 | Truist | Buy |
| 2022-02-18 | 개시 | RBC Capital Mkts | Outperform |
| 2021-12-01 | 개시 | Oppenheimer | Outperform |
| 2021-11-30 | 개시 | H.C. Wainwright | Buy |
| 2021-11-15 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-08-17 | 개시 | BofA Securities | Buy |
| 2021-08-17 | 개시 | Citigroup | Neutral |
| 2021-08-17 | 개시 | SVB Leerink | Outperform |
모두보기
Caribou Biosciences Inc 주식(CRBU)의 최신 뉴스
Are Medical Stocks Lagging Caribou Biosciences (CRBU) This Year? - Yahoo Finance
Multiple Myeloma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Poseida Therapeutics - Barchart
The Gross Law Firm Notifies Shareholders of Caribou Biosciences, - GuruFocus
Caribou Biosciences stock holds focus on CRISPR therapies - ad-hoc-news.de
Caribou Biosciences Inc (CRBU) Institutional Confidence - TradingKey
Caribou Biosciences, Inc.(NasdaqGS: CRBU) added to Russell 2000 Index - marketscreener.com
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Investing News Network
Caribou Biosciences, Inc.(NasdaqGS:CRBU) added to Russell Microcap Value Benchmark Index - marketscreener.com
Caribou Biosciences, Inc.(NasdaqGS: CRBU) added to Russell 2000 Value Benchmark - marketscreener.com
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewswire Inc.
Caribou Biosciences, Inc.(NasdaqGS: CRBU) added to Russell Microcap Index - marketscreener.com
Caribou Biosciences, Inc.(NasdaqGS:CRBU) added to Russell Small Cap Completeness Index - marketscreener.com
CRBUCaribou Biosciences Inc Latest SEC Filings - Finviz
Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences - The National Law Review
Caribou Biosciences, Inc.(NasdaqGS: CRBU) added to Russell 3000 Index - marketscreener.com
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirt - The National Law Review
Caribou Biosciences Inc (CRBU) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Caribou Biosciences, Inc. Actuals & Estimates (NASDAQ:CRBU) - TradingView
CRBU Forecast — Price Target — Prediction for 2027 - TradingView
Caribou Biosciences Inc (CRBU) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Caribou Biosciences StockLong-term CRISPR strategy in focus - AD HOC NEWS
Caribou Biosciences Shareholders Decide Key Governance Matters - TipRanks
Caribou Biosciences (NASDAQ: CRBU) holders reject officer exculpation - Stock Titan
Caribou Biosciences Inc (CRBU) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Caribou Biosciences Inc (CRBU) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Caribou Biosciences Inc (CRBU) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CRBU Q1 2026 Earnings: EPS Beat Offers Little Reprieve as Stock SlipsTech Earnings Analysis - newsline.com
Caribou Biosciences Inc (CRBU) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Caribou Biosciences Inc (CRBU) Valuation: PE, PB & Fair Value Analysis - TradingKey
Caribou Biosciences Inc (CRBU) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
CRBU News | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill
H.C. Wainwright reiterates Caribou Biosciences stock rating at buy By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Caribou Biosciences stock rating at buy - Investing.com
Clinical: Caribous' Off-The-Shelf Car-T Drives Durable Myeloma Responses - CRISPR Medicine News
Investors who lost money on Caribou Biosciences, Inc.(CRBU) shou - GuruFocus
Longer-term CB-011 results unveiled by Caribou Biosciences at EHA2026 - Traders Union
Caribou Biosciences (CRBU) Slides 3.92%, Nears Critical Support at $1.51Catalyst Driven Stocks - newsline.com
Caribou Biosciences, Inc. (CRBU) Presents at European Hematology Association (EHA) 2026 CongressSlideshow - Seeking Alpha
Caribou Biosciences presents new data on allogeneic CAR-T cell programs at EHA - Traders Union
Citi Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026 - Investing News Network
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association Annual Meeting - Investing News Network
Caribou reports phase 1 trial data for off-the-shelf CAR-T therapy - Investing.com UK
Caribou Biosciences Reports Long-Term Vispa-Cel Data in Second-Line Large B Cell Lymphoma - marketscreener.com
Caribou reports phase 1 data for off-the-shelf CAR-T therapy - Investing.com UK
Caribou reports phase 1 data for off-the-shelf CAR-T therapy By Investing.com - Investing.com Australia
Caribou Biosciences Highlights Strong Allogeneic CAR-T Trial Results - TipRanks
CB-011 dose escalation data points to advances in relapsed multiple myeloma, Caribou Biosciences launches study update - Traders Union
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting - The Manila Times
Caribou Biosciences (CRBU) reports durable phase 1 CAR-T responses in lymphoma and myeloma - Stock Titan
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears - Yahoo Finance
Caribou Biosciences Inc (CRBU) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):